UCB

GREENVILLE, S.C., June 30, 2026 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) announces it will release its second quarter 2026 financial results on Tuesday, July 21, 2026, before the stock market opens. The company also will hold a conference call at 9:00 a.m. EDT on Tuesday, July 21, 2026, to discuss its financial results, business highlights, and outlook.

Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.1 Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression2 and highlights the benefits of early diagnosis.3 ATLANTA, June 17, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in Brain Communications. One manuscript reports integrated safety and efficacy findings for KYGEVVI® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on or before 12 years of age, demonstrating improved survival and functional outcomes in treated patients, along with acceptable tolerability.1 A second manuscript features findings from the largest published dataset of untreated patients with TK2d, illustrating the progressive burden of disease and increased risk of early death, thus reinforcing the importance of timely diagnosis and treatment.2 "TK2d can have a devastating impact on patients and families if left untreated, which the data compiled and published in Brain Communications confirm," said Caterina Garone, Associate Professor of Medical Genetics, University of Bologna, Italy, and co-author of both studies.

United Community Banks, Inc. (UCB) M&A Call Transcript

GREENVILLE, S.C., June 12, 2026 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) (“United”) today announced the execution of a definitive agreement to sell its equipment finance business, consisting of Navitas Credit Corp. and NLFC Reinsurance Corp. (collectively, “Navitas”), to funds managed by Wafra Inc., acting through Navitas TopCo LLC (“Wafra”) for $1.9 billion in cash1 (the “Transaction”).

GREENVILLE, S.C., May 14, 2026 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NYSE: UCB) (the “Company”), reported that its Board of Directors approved a quarterly cash dividend of $0.25 per share on the Company's common stock. The dividend is payable on July 3, 2026 to shareholders of record as of June 15, 2026.

The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.

United Community Banks, Inc. reported Q1 2026 adjusted EPS of $0.70, matching expectations, with modest improvements in net interest margin and asset quality. UCB announced the $100.8M acquisition of Peach State Bancshares, continuing its steady expansion strategy, but the deal is too small to materially shift the investment case. The stock trades at a forward P/E of 11.5 and a 1.48x price/TBV, both slightly above sector averages, while expected growth does not justify a premium valuation.

United Community Banks, Inc. (UCB) Q1 2026 Earnings Call Transcript

Although the revenue and EPS for United Community Banks (UCB) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

United Community Banks (UCB) came out with quarterly earnings of $0.7 per share, missing the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.59 per share a year ago.